Strategic role of nuclear inositide signalling in myelodysplastic syndromes therapy

Mini-Reviews in Medicinal Chemistry

Volumn 14, Issue 11, 2014, Pages 873-883

  Manzoli, Lucia ^a   Mongiorgi, Sara ^a   Clissa, Cristina ^b,c   Finelli, Carlo ^b   Billi, Anna Maria ^a   Poli, Alessandro ^a   Quaranta, Marilisa ^a   Cocco, Lucio ^a   Follo, Matilde Y ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

^c AORMN   (Italy)

Author keywords

Akt; Azacitidine; Erythroid differentiation; Erythropoietin; Myelodysplastic syndromes; Myeloid differentiation; Nuclear inositides; Phospholipase C 1

Indexed keywords

AZACITIDINE; CALCIUM; CYCLIN D3; DIACYLGLYCEROL; DNA METHYLTRANSFERASE; ERYTHROPOIETIN; G PROTEIN COUPLED RECEPTOR; HEMOGLOBIN; HISTONE DEACETYLASE; INOSITIDE; INOSITOL 1, 4, 5 TRISPHOSPHATE; MAMMALIAN TARGET OF RAPAMYCIN; MICRORNA; MICRORNA 155; MICRORNA 21; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 4, 5 BISPHOSPHATE PHOSPHODIESTERASE; PROTEIN KINASE B; PROTEIN KINASE B BETA; PROTEIN KINASE C; PROTEIN TYROSINE KINASE; RAF PROTEIN; RAS PROTEIN; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 4; SUGAR ALCOHOL; UNCLASSIFIED DRUG; VALPROIC ACID;

ACUTE GRANULOCYTIC LEUKEMIA; ARTICLE; BONE MARROW CELL; CELL DIFFERENTIATION; CELL PROLIFERATION; DNA DAMAGE; DNA METHYLATION; ENZYME ACTIVATION; EPIGENETICS; ERYTHROID CELL; ERYTHROPOIESIS; GENE EXPRESSION; HISTONE MODIFICATION; HUMAN; INTRACELLULAR SIGNALING; MYELODYSPLASTIC SYNDROME; PATHOGENESIS; PROTEIN PHOSPHORYLATION; PROTEIN SYNTHESIS;

EID: 84911415867     PISSN: 13895575     EISSN: 18755607     Source Type: Journal    
DOI: 10.2174/1389557514666141013125936     Document Type: Article

References (85)

1. Yang, Y.R.; Follo, M.Y.; Cocco, L.; Suh, P.G., The physiological roles of primary phospholipase C. Adv. Biol. Regul., 2013, 53, (3), 232-241.
2. Rhee, S.G., Reflections on the days of phospholipase C. Adv. Biol. Regul., 2013, 53, (3), 223-231.
3. Rhee, S.G., Regulation of phosphoinositide-specific phospholipase C. Annu. Rev. Biochem., 2001, 70, 281-312.
4. Smrcka, A.V.; Brown, J.H.; Holz, G.G., Role of phospholipase Cepsilon in physiological phosphoinositide signaling networks. Cellular Signalling, 2012, 24, (6), 1333-1343.
5. Kawakami, T.; Xiao, W., Phospholipase C-beta in immune cells. Adv. Biol. Regul., 2013, 53, (3), 249-257.
6. Koh, H.Y., Phospholipase C-beta1 and schizophrenia-related behaviors. Adv. Biol. Regul., 2013, 53, (3), 242-248.
7. Philip, F.; Sahu, S.; Caso, G.; Scarlata, S., Role of phospholipase C-beta in RNA interference. Adv. Biol. Regul., 2013, 53, (3), 319-330.
8. Martelli, A.M.; Gilmour, R.S.; Bertagnolo, V.; Neri, L.M.; Manzoli, L.; Cocco, L., Nuclear localization and signalling activity of phosphoinositidase C beta in Swiss 3T3 cells. Nature, 1992, 358, (6383), 242-245.
9. Ramazzotti, G.; Faenza, I.; Fiume, R.; Matteucci, A.; Piazzi, M.; Follo, M.Y.; Cocco, L., The physiology and pathology of inositide signaling in the nucleus. J. Cellular Physiol., 2011, 226, (1), 14-20.
10. Follo, M.Y.; Mongiorgi, S.; Finelli, C.; Clissa, C.; Ramazzotti, G.; Fiume, R.; Faenza, I.; Manzoli, L.; Martelli, A.M.; Cocco, L., Nuclear inositide signaling in myelodysplastic syndromes. J. Cellular Biochem., 2010, 109, (6), 1065-1071.
11. Faenza, I.; Billi, A.M.; Follo, M.Y.; Fiume, R.; Martelli, A.M.; Cocco, L.; Manzoli, L., Nuclear phospholipase C signaling through type 1 IGF receptor and its involvement in cell growth and differentiation. Antican. Res., 2005, 25, (3B), 2039-2041.
12. Martelli, A.M.; Fiume, R.; Faenza, I.; Tabellini, G.; Evangelista, C.; Bortul, R.; Follo, M.Y.; Fala, F.; Cocco, L., Nuclear phosphoinositide specific phospholipase C (PI-PLC)-beta 1: a central intermediary in nuclear lipid-dependent signal transduction. Histology and Histopathology, 2005, 20, (4), 1251-1260.
13. Follo, M.Y.; Faenza, I.; Piazzi, M.; Blalock, W.L.; Manzoli, L.; McCubrey, J.A.; Cocco, L., Nuclear PI-PLCbeta1: an appraisal on targets and pathology. Adv. Biol. Regul., 2014, 54, 2-11.
14. De Luca, G.; Ferretti, R.; Bruschi, M.; Mezzaroma, E.; Caruso, M., Cyclin D3 critically regulates the balance between self-renewal and differentiation in skeletal muscle stem cells. Stem cells (Dayton, Ohio), 2013, 31, (11), 2478-2491.
15. Poli A, Mongiorgi S, Cocco L, Follo MY. Protein kinase C involvement in cell cycle modulation. Biochem. Soc. Trans., 2014 42(5), 1471-1476.
16. Braccini, L.; Ciraolo, E.; Martini, M.; Pirali, T.; Germena, G.; Rolfo, K.; Hirsch, E., PI3K keeps the balance between metabolism and cancer. Adv. Biol. Regul., 2012, 52, (3), 389-405.
17. Porta, C.; Paglino, C.; Mosca, A., Targeting PI3K/Akt/mTOR Signaling in Cancer. Frontiers in Oncology, 2014, 4, 64.
18. Scholl, C.; Gilliland, D.G.; Frohling, S., Deregulation of signaling pathways in acute myeloid leukemia. Seminars in oncology, 2008, 35, (4), 336-345.
19. Chiarini, F.; Del Sole, M.; Mongiorgi, S.; Gaboardi, G.C.; Cappellini, A.; Mantovani, I.; Follo, M.Y.; McCubrey, J.A.; Martelli, A.M., The novel Akt inhibitor, perifosine, induces caspase-dependent apoptosis and downregulates P-glycoprotein expression in multidrug-resistant human T-acute leukemia cells by a JNK-dependent mechanism. Leukemia, 2008, 22, (6), 1106-1116.
20. Kumar, C.C.; Madison, V., AKT crystal structure and AKTspecific inhibitors. Oncogene, 2005, 24, (50), 7493-7501.
21. Fruman, D.A.; Rommel, C., PI3K and cancer: lessons, challenges and opportunities. Nat. Rev., 2014, 13, (2), 140-156.
22. Zinzalla, V.; Stracka, D.; Oppliger, W.; Hall, M.N., Activation of mTORC2 by association with the ribosome. Cell, 2011, 144, (5), 757-768.
23. Laplante, M.; Sabatini, D.M., mTOR signaling in growth control and disease. Cell, 2012, 149, (2), 274-293.
24. Huang, J.; Manning, B.D., The TSC1-TSC2 complex: a molecular switchboard controlling cell growth. Biochem. J., 2008, 412, (2), 179-190.
25. Dibble, C.C.; Elis, W.; Menon, S.; Qin, W.; Klekota, J.; Asara, J.M.; Finan, P.M.; Kwiatkowski, D.J.; Murphy, L.O.; Manning, B.D., TBC1D7 is a third subunit of the TSC1-TSC2 complex upstream of mTORC1. Mol. Cell, 2012, 47, (4), 535-546.
26. Guertin, D.A.; Stevens, D.M.; Saitoh, M.; Kinkel, S.; Crosby, K.; Sheen, J.H.; Mullholland, D.J.; Magnuson, M.A.; Wu, H.; Sabatini, D.M., mTOR complex 2 is required for the development of prostate cancer induced by Pten loss in mice. Cancer Cell, 2009, 15, (2), 148-159.
27. Janes, M.R.; Limon, J.J.; So, L.; Chen, J.; Lim, R.J.; Chavez, M.A.; Vu, C.; Lilly, M.B.; Mallya, S.; Ong, S.T.; Konopleva, M.; Martin, M.B.; Ren, P.; Liu, Y.; Rommel, C.; Fruman, D.A., Effective and selective targeting of leukemia cells using a TORC1/2 kinase inhibitor. Nat. Med., 2010, 16, (2), 205-213.
28. Ingley, E., Integrating novel signaling pathways involved in erythropoiesis. IUBMB life, 2012, 64, (5), 402-410.
29. Wang, Y.; Wu, J.; Wang, Z., Akt binds to and phosphorylates phospholipase C-gamma1 in response to epidermal growth factor. Mol. Biol. Cell, 2006, 17, (5), 2267-2277.
30. Marzo, F.; Lavorgna, A.; Coluzzi, G.; Santucci, E.; Tarantino, F.; Rio, T.; Conti, E.; Autore, C.; Agati, L.; Andreotti, F., Erythropoietin in heart and vessels: focus on transcription and signalling pathways. J. Thrombosis and Thrombolysis, 2008, 26, (3), 183-187.
31. Raimondi, C.; Falasca, M., Phosphoinositides signalling in cancer: focus on PI3K and PLC. Adv. Biol. Regul., 2012, 52, (1), 166-182.
32. Bouscary, D.; Pene, F.; Claessens, Y.E.; Muller, O.; Chretien, S.; Fontenay-Roupie, M.; Gisselbrecht, S.; Mayeux, P.; Lacombe, C., Critical role for PI 3-kinase in the control of erythropoietin-induced erythroid progenitor proliferation. Blood, 2003, 101, (9), 3436-3443.
33. Ghaffari, S.; Kitidis, C.; Zhao, W.; Marinkovic, D.; Fleming, M.D.; Luo, B.; Marszalek, J.; Lodish, H.F., AKT induces erythroid-cell maturation of JAK2-deficient fetal liver progenitor cells and is required for Epo regulation of erythroid-cell differentiation. Blood, 2006, 107, (5), 1888-1891.
34. Yang, Y.R.; Choi, J.H.; Chang, J.S.; Kwon, H.M.; Jang, H.J.; Ryu, S.H.; Suh, P.G., Diverse cellular and physiological roles of phospholipase C-gamma1. Adv. biol. regul., 2012, 52, (1), 138-151.
35. Garcia-Manero, G., Myelodysplastic syndromes: 2014 update on diagnosis, risk-stratification, and management. Am. J. Hematol., 2014, 89, (1), 97-108.
36. Visconte, V.; Makishima, H.; Jankowska, A.; Szpurka, H.; Traina, F.; Jerez, A.; O'Keefe, C.; Rogers, H.J.; Sekeres, M.A.; Maciejewski, J.P.; Tiu, R.V., SF3B1, a splicing factor is frequently mutated in refractory anemia with ring sideroblasts. Leukemia, 2012, 26, (3), 542-545.
37. Bennett, J.M.; Catovsky, D.; Daniel, M.T.; Flandrin, G.; Galton, D.A.; Gralnick, H.R.; Sultan, C., Proposals for the classification of the myelodysplastic syndromes. Br. J. Haematol., 1982, 51, (2), 189-199.
38. Lo Vasco, V.R.; Calabrese, G.; Manzoli, L.; Palka, G.; Spadano, A.; Morizio, E.; Guanciali-Franchi, P.; Fantasia, D.; Cocco, L., Inositide-specific phospholipase c beta1 gene deletion in the progression of myelodysplastic syndrome to acute myeloid leukemia. Leukemia, 2004, 18, (6), 1122-1126.
39. Follo, M.Y.; Finelli, C.; Clissa, C.; Mongiorgi, S.; Bosi, C.; Martinelli, G.; Baccarani, M.; Manzoli, L.; Martelli, A.M.; Cocco, L., Phosphoinositide-phospholipase C beta1 mono-allelic deletion is associated with myelodysplastic syndromes evolution into acute myeloid leukemia. J. Clin. Oncol., 2009, 27, (5), 782-790.
40. Damm, F.; Lange, K.; Heuser, M.; Oberack Morgan, M.; Wagner, K.; Krauter, J.; Schlegelberger, B.; Ganser Aer T.; Gohring, G., Phosphoinositide phospholipase Cbeta1 (PI-PLCbeta1) gene in myelodysplastic syndromes and cytogenetically normal acute myeloid leukemia: not a deletion, but increased PI-PLCbeta1 expression is an independent prognostic factor. J. Clin. Oncol., 2010, 28, (22), e384-387; author reply e388-389.
41. Follo, M.Y.; Finelli, C.; Mongiorgi, S.; Clissa, C.; Cocco, L., Reply to F. Damm A et al. J. Clin. Oncol., 2010, 28, (22), e388-e389.
42. Follo, M.Y.; Bosi, C.; Finelli, C.; Fiume, R.; Faenza, I.; Ramazzotti, G.; Gaboardi, G.C.; Manzoli, L.; Cocco, L., Real-time PCR as a tool for quantitative analysis of PI-PLCbeta1 gene expression in myelodysplastic syndrome. Intl. J. Mol. Med., 2006, 18, (2), 267-271.
43. Mongiorgi, S.; Follo, M.Y.; Clissa, C.; Giardino, R.; Fini, M.; Manzoli, L.; Ramazzotti, G.; Fiume, R.; Finelli, C.; Cocco, L., Nuclear PI-PLC beta1 and Myelodysplastic syndromes: from bench to clinics. Curr. Top. Microb. Immunol., 2012, 362, 235-245.
44. Follo, M.Y.; Mongiorgi, S.; Finelli, C.; Piazzi, M.; Faenza, I.; Ramazzotti, G.; Santi, P.; McCubrey, J.A.; Martelli, A.M.; Cocco, L., Nuclear PI-PLCbeta1 and myelodysplastic syndromes: genetics and epigenetics. Curr. Pharmaceutic. Des., 2012, 18, (13), 1751-1754.
45. Guida, M.; Maraldi, T.; Beretti, F.; Follo, M.Y.; Manzoli, L.; De Pol, A., Nuclear Nox4-derived reactive oxygen species in myelodysplastic syndromes. Biomed. Res. Int., 2014, 2014, 456937.
46. Tefferi, A.; Vardiman, J.W., Myelodysplastic syndromes. The New England journal of medicine, 2009, 361, (19), 1872-1885.
47. Mummaneni, P.; Shord, S.S., Epigenetics and oncology. Pharmacotherapy, 2014, 34, (5), 495-505.
48. Gal-Yam, E.N.; Saito, Y.; Egger, G.; Jones, P.A., Cancer epigenetics: modifications, screening, and therapy. Ann. Rev. Med., 2008, 59, 267-280.
49. Quintas-Cardama, A.; Santos, F.P.; Garcia-Manero, G., Histone deacetylase inhibitors for the treatment of myelodysplastic syndrome and acute myeloid leukemia. Leukemia, 2011, 25, (2), 226-235.
50. Minucci, S.; Pelicci, P.G., Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat. Rev. Cancer, 2006, 6, (1), 38-51.
51. Burton, A.; Azevedo, C.; Andreassi, C.; Riccio, A.; Saiardi, A., Inositol pyrophosphates regulate JMJD2C-dependent histone demethylation. Proceed. Nat. Acad. Sci. U.S.A., 2013, 110, (47), 18970-18975.
52. Garzon, R.; Croce, C.M., MicroRNAs in normal and malignant hematopoiesis. Curr. Opin. Hematol., 2008, 15, (4), 352-358.
53. Bhagat, T.D.; Zhou, L.; Sokol, L.; Kessel, R.; Caceres, G.; Gundabolu, K.; Tamari, R.; Gordon, S.; Mantzaris, I.; Jodlowski, T.; Yu, Y.; Jing, X.; Polineni, R.; Bhatia, K.; Pellagatti, A.; Boultwood, J.; Kambhampati, S.; Steidl, U.; Stein, C.; Ju, W.; Liu, G.; Kenny, P.; List, A.; Bitzer, M.; Verma, A., miR-21 mediates hematopoietic suppression in MDS by activating TGF-beta signaling. Blood, 2013, 121, (15), 2875-2881.
54. Kim, Y.; Cheong, J.W.; Kim, Y.K.; Eom, J.I.; Jeung, H.K.; Kim, S.J.; Hwang, D.; Kim, J.S.; Kim, H.J.; Min, Y.H., Serum microRNA-21 as a potential biomarker for response to hypomethylating agents in myelodysplastic syndromes. PloS One, 2014, 9, (2), e86933.
55. Lee, D.W.; Futami, M.; Carroll, M.; Feng, Y.; Wang, Z.; Fernandez, M.; Whichard, Z.; Chen, Y.; Kornblau, S.; Shpall, E.J.; Bueso-Ramos, C.E.; Corey, S.J., Loss of SHIP-1 protein expression in high-risk myelodysplastic syndromes is associated with miR-210 and miR-155. Oncogene, 2012, 31, (37), 4085-4094.
56. Kerbauy, D.B.; Deeg, H.J., Apoptosis and antiapoptotic mechanisms in the progression of myelodysplastic syndrome. Exp. hematol., 2007, 35, (11), 1739-1746.
57. Pang, W.W.; Pluvinage, J.V.; Price, E.A.; Sridhar, K.; Arber, D.A.; Greenberg, P.L.; Schrier, S.L.; Park, C.Y.; Weissman, I.L., Hematopoietic stem cell and progenitor cell mechanisms in myelodysplastic syndromes. Proceed. Nat. Acad. Sci. U.S.A, 2013, 110, (8), 3011-3016.
58. Jelkmann, W., Physiology and pharmacology of erythropoietin. Transfus. Med. Hemother., 2013, 40, (5), 302-309.
59. Elliott, S.; Sinclair, A.M., The effect of erythropoietin on normal and neoplastic cells. Biologics, 2012, 6, 163-189.
60. Buck, I.; Morceau, F.; Cristofanon, S.; Heintz, C.; Chateauvieux, S.; Reuter, S.; Dicato, M.; Diederich, M., Tumor necrosis factor alpha inhibits erythroid differentiation in human erythropoietindependent cells involving p38 MAPK pathway, GATA-1 and FOG-1 downregulation and GATA-2 upregulation. Biochem. Pharmacol., 2008, 76, (10), 1229-1239.
61. Tong, Q.; Hirschler-Laszkiewicz, I.; Zhang, W.; Conrad, K.; Neagley, D.W.; Barber, D.L.; Cheung, J.Y.; Miller, B.A., TRPC3 is the erythropoietin-regulated calcium channel in human erythroid cells. J. Biol. Chem., 2008, 283, (16), 10385-10395.
62. Santini, V., Treatment of low-risk myelodysplastic syndrome: hematopoietic growth factors erythropoietins and thrombopoietins. Seminars in Hematology, 2012, 49, (4), 295-303.
63. Garcia-Manero, G.; Fenaux, P., Hypomethylating agents and other novel strategies in myelodysplastic syndromes. J. Clin. Oncol., 2011, 29, (5), 516-523.
64. Jadersten, M.; Malcovati, L.; Dybedal, I.; Della Porta, M.G.; Invernizzi, R.; Montgomery, S.M.; Pascutto, C.; Porwit, A.; Cazzola, M.; Hellstrom-Lindberg, E., Erythropoietin and granulocyte-colony stimulating factor treatment associated with improved survival in myelodysplastic syndrome. J. Clin. Oncol., 2008, 26, (21), 3607-3613.
65. Ramazzotti, G.; Faenza, I.; Follo, M.Y.; Fiume, R.; Piazzi, M.; Giardino, R.; Fini, M.; Cocco, L., Nuclear phospholipase C in biological control and cancer. Critical Rev. Eukaryotic Gene Expression, 2011, 21, (3), 291-301.
66. di Giacomo, V.; Matteucci, A.; Stellacci, E.; Battistini, A.; Di Baldassarre, A.; Capitani, S.; Alfani, E.; Migliaccio, A.R.; Cocco, L.; Migliaccio, G., Expression of signal transduction proteins during the differentiation of primary human erythroblasts. J. Cell. Physiol., 2005, 202, (3), 831-838.
67. Follo, M.Y.; Mongiorgi, S.; Clissa, C.; Paolini, S.; Martinelli, G.; Martelli, A.M.; Fioravanti, G.; Manzoli, L.; Finelli, C.; Cocco, L., Activation of nuclear inositide signalling pathways during erythropoietin therapy in low-risk MDS patients. Leukemia, 2012, 26, (12), 2474-2482.
68. Missiroli, S.; Etro, D.; Buontempo, F.; Ye, K.; Capitani, S.; Neri, L.M., Nuclear translocation of active AKT is required for erythroid differentiation in erythropoietin treated K562 erythroleukemia cells. Int. J. Biochem. Cell Biol., 2009, 41, (3), 570-577.
69. Garcia-Manero, G., Treatment of higher-risk myelodysplastic syndrome. Seminars in Oncology, 2011, 38, (5), 673-681.
70. Fili, C.; Malagola, M.; Follo, M.Y.; Finelli, C.; Iacobucci, I.; Martinelli, G.; Cattina, F.; Clissa, C.; Candoni, A.; Fanin, R.; Gobbi, M.; Bocchia, M.; Defina, M.; Spedini, P.; Skert, C.; Manzoli, L.; Cocco, L.; Russo, D., Prospective phase II Study on 5- days azacitidine for treatment of symptomatic and/or erythropoietin unresponsive patients with low/INT-1-risk myelodysplastic syndromes. Clin. Cancer Res., 2013, 19, (12), 3297-3308.
71. Musto, P.; Maurillo, L.; Spagnoli, A.; Gozzini, A.; Rivellini, F.; Lunghi, M.; Villani, O.; Aloe-Spiriti, M.A.; Venditti, A.; Santini, V., Azacitidine for the treatment of lower risk myelodysplastic syndromes : a retrospective study of 74 patients enrolled in an Italian named patient program. Cancer, 2010, 116, (6), 1485-1494.
72. Fenaux, P.; Ades, L., Review of azacitidine trials in Intermediate-2- and High-risk myelodysplastic syndromes. Leukemia Res., 2009, 33 Suppl 2, S7-11.
73. Silverman, L.R., DNA methyltransferase inhibitors in myelodysplastic syndrome. Best Pract. Res., 2004, 17, (4), 585-594.
74. Follo, M.Y.; Finelli, C.; Bosi, C.; Martinelli, G.; Mongiorgi, S.; Baccarani, M.; Manzoli, L.; Blalock, W.L.; Martelli, A.M.; Cocco, L., PI-PLCbeta-1 and activated Akt levels are linked to azacitidine responsiveness in high-risk myelodysplastic syndromes. Leukemia, 2008, 22, (1), 198-200.
75. Follo, M.Y.; Finelli, C.; Mongiorgi, S.; Clissa, C.; Bosi, C.; Testoni, N.; Chiarini, F.; Ramazzotti, G.; Baccarani, M.; Martelli, A.M.; Manzoli, L.; Martinelli, G.; Cocco, L., Reduction of phosphoinositide-phospholipase C beta1 methylation predicts the responsiveness to azacitidine in high-risk MDS. Proceed. Nat. Acad. Sci. U.S.A., 2009, 106, (39), 16811-16816.
76. Song, J.J.; Liu, Q.; Li, Y.; Yang, Z.S.; Yang, L.; Xiang, T.X.; Ren, G.S.; Chen, J.B., Epigenetic inactivation of PLCD1 in chronic myeloid leukemia. Int. J. Mol. Med., 2012, 30, (1), 179-184.
77. Kouzarides, T., Chromatin modifications and their function. Cell, 2007, 128, (4), 693-705.
78. Johnstone, R.W.; Licht, J.D., Histone deacetylase inhibitors in cancer therapy: is transcription the primary target? Cancer Cell, 2003, 4, (1), 13-18.
79. Griffiths, E.A.; Gore, S.D., DNA methyltransferase and histone deacetylase inhibitors in the treatment of myelodysplastic syndromes. Seminars in Hematology, 2008, 45, (1), 23-30.
80. Gore, S.D.; Hermes-DeSantis, E.R., Future directions in myelodysplastic syndrome: newer agents and the role of combination approaches. Cancer Control, 2008, 15 Suppl, 40-49.
81. Voso, M.T.; Santini, V.; Finelli, C.; Musto, P.; Pogliani, E.; Angelucci, E.; Fioritoni, G.; Alimena, G.; Maurillo, L.; Cortelezzi, A.; Buccisano, F.; Gobbi, M.; Borin, L.; Di Tucci, A.; Zini, G.; Petti, M.C.; Martinelli, G.; Fabiani, E.; Fazi, P.; Vignetti, M.; Piciocchi, A.; Liso, V.; Amadori, S.; Leone, G., Valproic acid at therapeutic plasma levels may increase 5-azacytidine efficacy in higher risk myelodysplastic syndromes. Clin. Cancer Res., 2009, 15, (15), 5002-5007.
82. Follo MY, Finelli C, Mongiorgi S, Clissa C, Chiarini F, Ramazzotti G, Paolini S, Martinelli G, Martelli AM, Cocco L. Synergistic induction of PI-PLCβ1 signaling by azacitidine and valproic acid in high-risk myelodysplastic syndromes. Leukemia, 2011, 25(2), 271-80.
83. Galdieri, L.; Chang, J.; Mehrotra, S.; Vancura, A., Yeast phospholipase C is required for normal acetyl-CoA homeostasis and global histone acetylation. J. Biol. Chem., 2013, 288, (39), 27986-27998.
84. Follo, M.Y.; Russo, D.; Finelli, C.; Mongiorgi, S.; Clissa, C.; Fili, C.; Colombi, C.; Gobbi, M.; Manzoli, L.; Piazzi, M.; Martelli, A.M.; Cocco, L., Epigenetic regulation of nuclear PI-PLCbeta1 signaling pathway in low-risk MDS patients during azacitidine treatment. Leukemia, 2012, 26, (5), 943-950.
85. Follo, M.Y.; Mongiorgi, S.; Bosi, C.; Cappellini, A.; Finelli, C.; Chiarini, F.; Papa, V.; Libra, M.; Martinelli, G.; Cocco, L.; Martelli, A.M., The Akt/mammalian target of rapamycin signal transduction pathway is activated in high-risk myelodysplastic syndromes and influences cell survival and proliferation. Cancer Res., 2007, 67, (9), 4287-4294